1st half day 2nd half day dash 1st half month 2nd half month dash 1st digit year 2nd digit year 3rd digit year last digit year
Sales of Cialis Rise

Written by Stuart Stevens | Monday, 24 July 2006 | There are 0 comments

Sales of the erectile dysfunction drug Cialis continue to rise with the companies Eli Lilly and ICOS reporting that sales reached 233.2 million dollars globally in the 2nd quarter of this year. The figure is a clear 22% rise in sales comared to the same period last year.

Cialis is belongs to 2 companies, Eli Lilly and ICOS and they anounced that the profit that accompanied these sales was 75.8 million for the 2nd quarter which compares favourably to the last years 2nd quarter loss of 1.7 million dollars. While it is true that the global market ofr erectile dysfunction medication increased last year and so the sales of Cialis were expected to grow it appears that the Cialis gained more than the general increase and have managed to increase market share overall. The profits were increased substantially also due the fact that  Eli Lilly and ICOS reduced spending on sales admin as well as in all areas of operational costs to the tune of 36 million dollars.

In America which still is the largest single market for erectile dysfunction drugs, the Cialis drug claimed a market share of over a quarter at 26.1% for the month of June that represents a rise of 2.8% when compared for June 2005. Lilly Icos as the joint venture is known is aggressively marketing the sales of its erectile dysfunction drug and has plans to introduce a new once a day version of the Cialis pill so that men who require to use ED medication often will be in a position to respond to sexual stimuli at all times rather than after they have taken the Cialis. At present the Once A Day version of Cialis is being looked at by the EMEA and the FDA in so that proper licencing and regulation can be obtained. Cialis is known as the Weekend Pill because its effects can last for 36 hours compared to 4 hours for the rivals Viagra and Levitra.

Cialis whose active ingredient is tadalafil has been also tested for use in patients with enlarged prostate glands and hypertension as well as pulmonary arterial hypertension (PAH).  The share price of ICOS rose 5% to reach 21.36 dollars on the news of the profits and sales.

© 2009 This content has been exclusively written by UKMedix [request source information]
ChatterBack with UKMedixGoto ChatterBack with UKMedix

There are 0 comments on this article.

Name :  *
Comment :  *
  Secure Image
Code :  * (please enter the code above)
 

Fields marked with  * are required.